1991 IPO

Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals is focused on the development of pharmaceutical products for the treatment of serious medical conditions.

Sign up today and learn more about Regeneron Pharmaceuticals Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Regeneron Pharmaceuticals Stock

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Funding History

August 2016$8.9M


Vice President, Head, Regeneron Genetics Center

Aris Baras

Manager, Combination Products Engineering

Michael Selzer

Executive Vice President, Research and Development

Neil Stahl

Senior Vice President, Regulatory Affairs

Ned Braunstein

Senior Vice President, Human Resources

Sally Paull

Senior Staff Engineer, Bioreactor Scale-Up and Development

Ashley Witmer

Senior Director, Business Development

Phil Gutry

Founder, President, and Chief Executive Officer

Leonard S. Schleifer

Associate Director

Amy Johnson

Sr Director

Serge Monpoeho

EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: